Market News & Trends
CytomX Announces Selection by Bristol-Myers Squibb of First Clinical Candidate
CytomX Therapeutics, Inc. recently announced that Bristol-Myers Squibb has selected a clinical candidate for its CTLA-4 Probody program under the strategic oncology collaboration established in…
Domain Therapeutics Grants Alkermes Non-Exclusive License for Technology
Domain Therapeutics recently announced the signing of a licensing agreement for its GPCR BioSens-All technology with Alkermes, a biopharmaceutical company that focuses on developing medicines…
C3J Therapeutics Unveils Development of Two New Product Formulations
C3J Therapeutics, Inc. recently announced the development of two new formulations of its lead candidate, C16G2, a novel peptide-based drug for the prevention of dental…
Achaogen Announces Positive Results in Phase III Trials
Achaogen, Inc. recently announced its lead product candidate, plazomicin, met the objective of non-inferiority compared to meropenem for the US FDA and achieved superiority for the…
Lonza to Acquire Capsugel to Create Leading Integrated Solutions Provider to the Global Pharma & Consumer Healthcare Industries
Lonza Group AG, KKR, and Capsugel S.A. recently announced they have entered into a definitive agreement under which Lonza will acquire Capsugel from KKR for…
Vetter's Skokie Site Successfully Manufactures Batches on New Clinical Syringe Filling Line
Vetter, a leading international contract development and manufacturing organization (CDMO) that specializes in aseptic filling for its (bio-)pharmaceutical customers, recently announced that its new clinical…
Catalent Biologics Collaborates With PATH Malaria Vaccine Initiative to Create Antibodies for Malaria Vaccine R&D
Catalent Pharma Solutions recently announced it has signed an agreement with PATH, an international non-profit organization and a leader in global health innovation, to advance…
GW Pharmaceuticals Announces New Positive Phase III Data
GW Pharmaceuticals plc recently announced additional positive Epidiolex (cannabidiol or CBD) Phase III data in poster presentations at the 70th Annual Meeting of the American…
Aptar Pharma Nears Completion of Elastomer Component Capacity
Aptar Pharma, a leading provider of drug delivery systems, is nearing completion on its expansion at its Congers, NY, state-of-the-art manufacturing site. The new space…
Immune Design Provides Update From Two Discovery Platforms
Immune Design recently announced new data that highlight the broad product reach potential of both its Specific Antigen and Endogenous Antigen/Intratumoral immunization approaches. ZVexMulti offers…
G1 Therapeutics Announces Clinical Trial Collaboration With Genentech
G1 Therapeutics recently announced a clinical trial collaboration with Genentech, a member of the Roche Group. A Phase II clinical trial is expected to begin…
Amgen & Allergan Submit Biosimilar Marketing Authorization Application
Amgen and Allergan plc. recently announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215, a biosimilar…
Impel NeuroPharma Announces $36-Million Funding to Advance Novel Delivery Platform
Impel NeuroPharma, Inc. recently announced that it has closed a Series C funding round in an amount up to $36 million to advance its novel…
Catalent Becomes First CDMO to Join Pharmaceutical Supply Chain Initiative
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, recently announced that it had…
VBL Therapeutics Announces Overall Survival Data for VB-111 Monotherapy in Phase 2 Study
VBL Therapeutics recently announced top-line results from its exploratory Phase II study of VB-111 (ofranergene obadenovec) in patients with advanced, differentiated thyroid cancer. As previously…
OncoMed Presents Initial First-in-Human Data
OncoMed Pharmaceuticals Inc. presented initial first-in-human data from its ongoing Phase I clinical trials of anti-DLL4/VEGF bispecific (OMP-305B83) and anti-RSPO3 (OMP-131R10) antibodies in two posters…
Catalent Acquires Company to Expand Softgel Development & Manufacturing
Catalent, Inc. recently announced it has agreed to acquire Accucaps Industries Limited (Accucaps), the Canada-based developer and manufacturer of Over-the-Counter (OTC), high-potency, and conventional pharmaceutical…
Ablynx Achieves First Milestone From Novo Nordisk
Ablynx recently announced it has achieved an initial discovery milestone with a multi-specific Nanobody construct as part of its collaboration with Novo Nordisk, triggering a…
Novan Announces Statistically Significant Phase II Clinical Trial Results
Novan, Inc. recently announced top-line results from the company’s Phase II clinical trial with SB206 for the treatment of genital warts caused by human papillomavirus,…
Cellular Biomedicine Group Approved to Commence Phase I Trial
Cellular Biomedicine Group Approved to Commence Phase I Trial Cellular Biomedicine Group Inc. (CBMG) recently announced the approval and commencement of patient enrollment in China…
